Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
picibanil
- Development stage
- Unknown
- Lead developer
- Fukushima Medical University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intratumoral
01
Overview
Picibanil is a lyophilized, nonreplicating biological preparation derived from the low-virulence Su strain of group A *Streptococcus pyogenes* after penicillin and heat treatment. It functions as a nonspecific immunostimulatory anticancer agent, activating innate immune signaling through the Toll-like receptor 4 and MD-2 pathway, promoting cytokine production and dendritic-cell maturation. In the Fukushima Medical University pancreatic-cancer program, picibanil was administered intratumorally with separately prepared immature dendritic cells before surgery in patients with resectable pancreatic cancer. ([academic.oup.com](https://academic.oup.com/jnci/article/95/4/316/2520610))
02
Targets
LY96 (Myeloid differentiation factor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on picibanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on picibanil.